Reviva Pharmaceuticals (RVPH) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights – 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – Cupertino, Calif., November 14, 2024 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Revi ...